Dr. Madduri on Challenges in Transplant-Eligible Patients With Myeloma
Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses challenges in the transplant-eligible myeloma population.
Related Articles
MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma
An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.
FDA Approves Cologuard Plus for Adults at Average Risk for CRC
The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk…
Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm
Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.
Long-Term Data Add to Prognostic Value of TILs in Treatment De-Escalation in Early HER2+ Breast Cancer
Maria Vittoria Dieci, MD, discusses the prognostic value of tumor-infiltrating lymphocytes in patients with early HER2-positive breast cancer.
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.
The OncFive: Top Oncology Articles for the Week of 9/15
Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.
Phase 2 Data Point to Potential Predictive Biomarkers for Benefit With Second-Line CM24 Combo in PDAC
Serum MPO, CEACAM1 positivity, and PD-L1 CPS could predict benefit with CM24-based therapy in second-line pancreatic ductal adenocarcinoma.
FDA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.
Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer
The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer.
Subcutaneous Daratumumab Quadruplet Approaches EU Approval for Newly Diagnosed Myeloma
The EMA’s CHMP has recommended the approval of subcutaneous daratumumab plus VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.